The primary endpoints of TROPION-Lung02 are dose-limiting toxicities and treatment-emergent adverse events. Secondary endpoints include ORR, DoR, PFS as assessed by investigator, overall survival, ...

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

Tweaking the pirfenidone molecule yields an evidently effective but less toxic antifibrotic drug, investigators say.

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

The test processes whole-slide images of non-small cell lung cancer tissue to provide a quantitative TROP2 score, which Roche says provides a level of precision beyond manual methods. TROP2 has ...

Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy We enrolled 32 patients with advanced NSCLC who tested positive for ROS1 ...

This was a multicenter, open-label, single-arm, phase II study in Korea (KCSG ... documented history of interstitial lung disease; active infection requiring systemic therapy; or uncontrolled ...

Roy Castle Lung Cancer Foundation is calling for an end to “smoker” and “non-smoker” labels, claiming they can have a “direct impact” on the speed at which the illness is detected.